Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01036165 · ClinicalTrials.gov registry record · Phase 3
A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study
A Phase 3 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 3
- Development phase
- 103
- Enrollment target
NCT01036165 is a Phase 3 study that has completed, run by EMD Serono. The registered enrollment target is 103 participants.
The verdict
NCT01036165, a Phase 3 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 103 participants
- Enrollment target
Study Summary
The purpose of this study is to test the RebiSmart™ for * ease of use * multiple domains related to subject's acceptability and satisfaction * reliability of the correct function for self-injection of Rebif® 44 mcg sc tiw in subjects with RMS.
Interventions
- DEVICE RebiSmart™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01036165
The ClinicalTrials.gov registry entry for NCT01036165 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RebiSmart™ is the first listed.
NCT01036165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01036165 about?
NCT01036165 is a clinical study titled "A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study". The purpose of this study is to test the RebiSmart™ for * ease of use * multiple domains related to subject's acceptability and satisfaction * reliability of the correct function for self-injection of Rebif® 44 mcg sc tiw in subjects with RMS.
What is the current status of trial NCT01036165?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 103 participants. The study started on 2010-01. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01036165?
The interventions under investigation include: RebiSmart™ (DEVICE).
Who is sponsoring clinical trial NCT01036165?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.